NetScientific PLC (LON:NSCI) portfolio company Glycotest has strengthened the protections around its new liver disease diagnostic with an exclusive patent in Europe.
It adds to patents already issued in the US, Japan and Australia covering 50 unique glycoprotein biomarkers and related assay technology that can diagnose liver cancer and other liver diseases.
Lead product, HCC Panel, has so far signfiicantly outperformed the current dominant blood test (AFP) in separate 208 and 127 patient head-to-head clinical studies, with further clinical validation expected over the second half of the year, said Francois Martelet, the chief executive of Netscientific and chairman of Glycotest.
NetScientific holds an 87.5% stake (67% on a fully diluted basis) in Glycotest.
"We are very pleased to announce international strengthening of the IP landscape controlled by Glycotest in the field of liver diagnostics,” said Martelet.
“The patents provide the foundation for future value enhancement and represent a critical step on Glycotest's road to commercialisation.”